About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

American Kidney Fund Announces April 30 as the First Annual APOL1-Mediated Kidney Disease (AMKD) Awareness Day

By: via GlobeNewswire

ROCKVILLE, Md., Jan. 25, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) is proud to announce that April 30, 2024 will mark the nation’s first ever AMKD Awareness Day. Building on AKF’s educational campaign for the condition, AMKD Awareness Day aims to spread awareness of APOL1-mediated kidney disease (AMKD), a spectrum of kidney diseases associated with variants (mutations) in the apolipoprotein L1 (APOL1) gene and linked to an increased risk for rapidly progressing kidney disease in people of Western and Central African descent.

Everyone has two copies of the APOL1 gene, but people who have Western and Central African ancestry, including people who identify as Black, African American, Afro-Caribbean, and/or Latina/Latino, are at an increased risk of having a mutation in one or both of the genes. People with two mutations are at higher risk of developing genetic forms of kidney disease such as focal segmental glomerulosclerosis (FSGS).

It is estimated that 13% of Black Americans have two mutations of the APOL1 gene, and these individuals have a 1 in 5 chance of developing kidney disease.  

“The discovery of APOL1 variants less than 20 years ago was hailed as a significant breakthrough, and we now have a better understanding of how the APOL1 variants have played a role in health disparities in kidney disease,” said AKF President and CEO LaVarne A. Burton. “In the United States, people of color are at increased risk for developing kidney failure, with Black Americans being four times more likely to need dialysis or a transplant. Unfortunately, not nearly enough people know about AMKD. We believe it is critical to raise national awareness of AMKD so that people will better understand their risk, start a conversation within their families and communities and be empowered to take action to protect their health, including consulting with a genetic counselor.”

“Establishing this inaugural annual AMKD Awareness Day represents a significant and proud moment for the kidney health community,” said Amit Sachdev, Chief Patient and External Affairs Officer at Vertex Pharmaceuticals. “We are honored to support AKF in highlighting the importance of increasing awareness of this disease and driving efforts to expand access to education and genetic testing resources.”

Coinciding with National Minority Health Month, AMKD Awareness Day will be recognized annually on the last Tuesday of April. AKF will be hosting an event on Capitol Hill in April to share resources and information with members of Congress and the public. Additionally, AKF will provide resources and ways to engage and raise awareness of the important connection between APOL1 gene variants and kidney disease in the months ahead. In the meantime, advocates and members of the public can help bring attention to AMKD among state legislatures across the country by requesting a proclamation from their governor.

Find updates and more information at KidneyFund.org/AMKD-Day.  

Support for AMKD Awareness Day is provided by Vertex Pharmaceuticals Incorporated.

###

About the American Kidney Fund

The American Kidney Fund (AKF) fights kidney disease on all fronts as the nation’s leading kidney nonprofit. AKF works on behalf of the 37 million Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease—from prevention through transplant. With programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy, no kidney organization impacts more lives than AKF. One of the nation’s top-rated nonprofits, AKF invests 97 cents of every donated dollar in programs, earning the highest 4-Star rating from Charity Navigator for 21 years in a row as well as the Platinum Seal of Transparency from Candid, formerly GuideStar.

For more information, please visit KidneyFund.org, or connect with us on Facebook, Twitter, Instagram and LinkedIn.


Nancy Gregory
American Kidney Fund
(240) 292-7077
ngregory@kidneyfund.org

More News

View More
Fastenal Stock Pulls Back in October—Is It Time to Buy FAST?
Via MarketBeat
Tickers FAST
Why Congress Is Buying Intuitive Surgical Ahead of Earnings
Via MarketBeat
Tickers ISRG XLV
FICO’s Big Dip Could Be the Best Buying Chance of the Year
Via MarketBeat
Tickers EFX FICO
D-Wave: Reevaluating the Short Seller’s Case After the Downgrade
Via MarketBeat
Tickers QBTS RGTI
Datavault: A Speculative AI Play, But Beware of Volatility
Via MarketBeat
Topics Artificial Intelligence
Tickers DVLT IBM SCLX
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.